Search - tctmd.com

Displaying 21 - 40 of 1102

Sort: Relevancy | Date

Presentation ESC 2025

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

Presenter: David Newby

September 03, 2025

Presentation ESC 2025

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

Presenter: Anders Jeppsson

September 01, 2025

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Todd Neale

September 01, 2025

Presentation ESC 2025

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

Presenter: Pedro A. Lemos

August 30, 2025

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

SCAI/HRS Issue First Practice Guideline for LAAO

Yael L. Maxwell

August 06, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Conference News EHRA 2025

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

Todd Neale

April 09, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2025

Caitlin E. Cox

April 01, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

Advertisement

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

DAPT De-escalation Success Varies by Sex: Meta-analysis

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

SCAI/HRS Issue First Practice Guideline for LAAO

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

TCTMD’s Top 10 Most Popular Stories for March 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

What’s Going to Be Hot at ACC 2025?

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content